Humacyte shares rise 1.95% in premarket after Symvess product gains approval for defense and veterans' medical facilities.

Humacyte, Inc. surged 1.95% in premarket trading, after the company announced that its vascular product Symvess has been approved for listing on the ECAT electronic catalog by the U.S. Defense Logistics Agency, allowing for procurement in Department of Defense and Veterans Affairs medical facilities. Humacyte focuses on developing bioengineered implantable human tissues, with a product line covering vascular repair, reconstruction, and replacement for indications such as trauma and dialysis.